Report

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over: technology appraisal guidance

By -

Publication details

Publication date
Pages
pp. 1–31
Publisher
National Institute for Health and Care Excellence (NICE)
View on nice.org.uk

Summary

Overview:
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

Last reviewed: 08 October 2025

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Notes

References: Pennington, B.M., Alava, M.H., and Strong, M. (2025) 'Unpaid caring and heath-related quality of life: longitudinal analysis of Understanding Society (the UK Household Longitudinal Survey)', Value in Health, 28(1):138-147. https://doi.org/10.1016/j.jval.2024.08.004

Topics